睿昂基因(688217.SH):公司的淋巴細胞基因重排產品具有“更早、更快、更精準”的特點
格隆匯4月28日丨有投資者向睿昂基因(688217.SH)提問:請問公司淋巴瘤基因重排試劑盒的優勢是什麼?
睿昂基因回覆:淋巴瘤的異常細胞和正常的淋巴細胞在形態視覺上面有差異,但是差異很難區分,只有少數全國大型醫院的醫生可以通過病理切片診斷出淋巴瘤,許多基層醫院的醫生沒有相應的能力能夠診斷出淋巴瘤,導致許多患者被誤診、漏診,失去了最佳的治療期。公司於2020年9月獲批的淋巴瘤基因重排產品,是國內淋巴瘤領域第一個獲批上市的分子診斷試劑產品。公司的淋巴細胞基因重排產品具有“更早、更快、更精準”的特點,檢測週期為8天,檢測準確度總體符合率達到99.12%。基層醫院的病理科醫生只要按照標準的操作程序,就可以利用公司的淋巴瘤基因重排試劑盒對患者進行檢測,這樣可以極大提高基層醫院的淋巴瘤的診斷水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.